This NGFR-spaced CD44v6 CAR T-cell product is currently at late stage of process development and these efforts have recently gained momentum by the EC through dedicated H2020 funding to support phase I/IIa clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) and multiple myeloma (MM). This evidence concerns the gene NGFR and Miyoshi myopathy.